Transparent Patient Adherence

Background

Historically, clinicians have been unable to proactively identify patients missing or shortening their Peritoneal Dialysis treatments.

Objectives

Method

Data on 399 European APD patients were analyzed

  • Patients that were utilizing an APD device with Sharesource Connectivity Platform for 3 months or more were examined for weekly treatment frequency and actual versus prescribed treatment time.
  • An assumption was made that patients perform APD therapy 7 days per week.
  • Patients with gaps in treatment > 30 days were omitted/excluded.
  • Time on treatment was determined from the first treatment after the training period to the last available treatment for a patient.
  • Weekly treatment frequency was the number of treatments in Sharesource Connectivity Platform / 30 * 7. E.g. If a patient had 27 treatments out of 30 days, then weekly rate = (27/30) * 7 = 6.3
  • Treatment differences were treatment time prescribed - actual treatment time performed.

Note: Claria with Sharesource was used in this study which is similar in function, design and indication to Amia with Sharesource

What have we seen so far?

bar graph of number of patients who missed treatment time of week by week therapy

In the 1st week of therapy

24.3% (97) and 9.5% (38) of patients had >100 minutes and >300 minutes, respectively, less actual therapy time than prescribed.

bar graph of number of missed treatments in the first month of dialysis

During the 1st month of therapy

30% (115) of patients missed >4 treatments (>10% of prescribed therapy) and 12% (47) of patients missed >9 treatments.

Bar chart of patients with at least 3 months of treatment who missed dwell time

In combined results of weeks 1, 2, 4 and 6*

  • 43% of patients missed >5% of prescribed dwell time
  • 20.6% of patients missed >10% of prescribed dwell time
  • 11.9% of patients missed >15% of prescribed dwell time
  • 7% of patients missed >20% of prescribed dwell time 

* Weeks 3 and 5 showed similar results to the weeks presented here. They were not included in the graphs and combined results for simplicity.

Conclusions

Sharesource Connectivity Platform with remote patient management allows clinicians to securely view their patient's daily home dialysis treatment data. 

Visibility to adherence patterns may provide opportunities for clinicians to intervene, educate or retrain the patient in a more timely manner. 

Clinicians using APD with Sharesource Connectivity Platform have greater visibility to patient adherence patterns which may allow early intervention.